July 21, 2021
Rohto Pharmaceutical said on July 20 that it has launched a Japanese PIII study for ROH-101, a topical ophthalmic form of the antiviral ganciclovir for the treatment of cytomegalovirus (CMV) corneal endotheliitis. The uncontrolled, open-label PIII study is designed to...read more